GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Hematology  (2)
  • Chen, Wei  (2)
Material
Publisher
  • American Society of Hematology  (2)
Language
Years
Subjects(RVK)
  • 1
    In: Blood, American Society of Hematology, Vol. 139, No. 26 ( 2022-06-30), p. 3752-3770
    Abstract: Differentiation blockade is a hallmark of acute myeloid leukemia (AML). A strategy to overcome such a blockade is a promising approach against the disease. The lack of understanding of the underlying mechanisms hampers development of such strategies. Dysregulated ribonucleotide reductase (RNR) is considered a druggable target in proliferative cancers susceptible to deoxynucleoside triphosphate (dNTP) depletion. Herein, we report an unanticipated discovery that hyperactivating RNR enables differentiation and decreases leukemia cell growth. We integrate pharmacogenomics and metabolomics analyses to identify that pharmacologically (eg, nelarabine) or genetically upregulating RNR subunit M2 (RRM2) creates a dNTP pool imbalance and overcomes differentiation arrest. Moreover, R-loop–mediated DNA replication stress signaling is responsible for RRM2 activation by nelarabine treatment. Further aggravating dNTP imbalance by depleting the dNTP hydrolase SAM domain and HD domain-containing protein 1 (SAMHD1) enhances ablation of leukemia stem cells by RRM2 hyperactivation. Mechanistically, excessive activation of extracellular signal-regulated kinase (ERK) signaling downstream of the imbalance contributes to cellular outcomes of RNR hyperactivation. A CRISPR screen identifies a synthetic lethal interaction between loss of DUSP6, an ERK-negative regulator, and nelarabine treatment. These data demonstrate that dNTP homeostasis governs leukemia maintenance, and a combination of DUSP inhibition and nelarabine represents a therapeutic strategy.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2022
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 1190-1190
    Abstract: Alterations of nuclear genes in human disease or tumors have been well investigated in past several decades and unequivocally established a predominant role in the pathogenesis. However, the relationship of mitochondrial genome alteration or dysfunction and human disease or tumor remains large unknown. Mitochondria are dynamic organelles involved in oxidative phosphorylation and production of reactive oxygen species (ROS). Accumulated evidence supports that mitochondrial DNA damage and dysfunction play vital roles in the development of a wide array of mitochondria-related diseases, such as obesity, diabetes, infertility, neurodegenerative disorders and malignant tumors in human. We previously described the development of a transgenic (TG) mouse model for mitochondrial damage by overexpressing human mitochondrial isoform of 8-oxoguanine DNA Glycosylase 1 (hOGG1) gene (Blood108:A 2246, 2006). The TG mice developed early onset obesity, female infertility, very high frequencies of B-cell lymphomas and human essential thrombocythemia like myeloproliferative disorders. We now reported here that major mitochondrial DNA deletions were frequently identified in a variety of organs in these hOGG1 TG mice and these deletions may largely contribute to the biologic phenotypes of the TG mice. The development and characterization of hOGG1 TG mice have been described previously. In the current study, mitochondrial DNA samples were extracted from various organs and tumor tissues of hOGG1 TG and age-matched non-TG control animals and subjected to PCR analysis using 8 specific primer sets franking the breakpoints of 7 major mitochondrial DNA deletions. Six deletions (3.7, 3.82, 3.86, 4.2, 4.9 and 5.2 kilobase in length) have been previously reported in the literatures. One novel deletion of 15.kilobase was identified in hOGG1 TG mouse in our laboratory. Among 7 major mitochondrial DNA deletion analyzed, Five (3.7, 3.86, 4.2, 5.2 and 15 kilobase in length) deletions were detected in higher frequency in various organs of hOGG1 TG but not in non-TG control mice, suggesting that those deletions might be resulted from overexpression of the transgene hOGG1. Notably, 3 deletions (del3729, del3868, and del15139) were identified in significantly higher in TG mouse spleen with myeloproliferative disorders or TG mouse spleen with diffuse large B-cell lymphoma, in comparison to the spleen of the age-matched wild type animals (P & lt;0.01). Accordingly, protein expression of major mitochondrial complexes were also significantly reduced in hOGG1 TG mice. Furthermore, major mitochondrial DNA deletion due to overexpressed hOGG1 leading to imbalanced mitochondrial DNA base excision repair pathways resulted in defects in mitochondrial respiration and significantly increased in ROS production in those TG mice. We therefore concluded that major mitochondrial DNA deletions with resultant reduced mitochondrial protein expression, mitochondrial dysfunction and increased in ROS production may represent an important molecular mechanism by which these hOGG TG mice develop obesity, infertility and hematologic malignancies.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...